BYON4228.001: First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Rituxan (rituximab) - Roche

BYON4228 - Byondis

Truxima (rituximab-abbs) - Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku

http://clinicaltrials.gov/ct2/show/NCT05737628

Jan 17, 2026